ISO1-1 Role of Cry genes in Development and Progression of Atherosclerosis
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan

Cardiovascular disease is a major and increasing cause of death worldwide. Epidemiologic studies suggest an important role of circadian rhythms in the cyclic variation of cardiac vulnerability and susceptibility to adverse cardiovascular events. Cry genes are indispensable genes for circadian clock in mammals. Genetic disruption of Cry genes resulted in loss of behavioral and physiological rhythmicity. However, there are no experimental data linking circadian rhythm with cardiovascular remodeling post injury. In this study we investigate the role of Cry genes in the development and progression of atherosclerosis using Cry deficient mice (KO) subjected to carotid ligation. KO and WT mice were kept in light-dark cycle and constant darkness during experiment. At basal condition KO mice (n=8) had significantly higher blood pressure as compared to WT mice (n=6) (135.8±7.0 vs 110.8±4.0 mmHg, p<0.0001). Four weeks after ligation, higher systolic blood pressure was observed in KO mice kept in both light-dark cycle as well as constant darkness than that of WT mice. KO and WT mice showed neointimal formation in the ligated arteries. However the extent of neointimal formation showed by Intimal Media Thickness Ratio was significantly higher in the KO mice kept in constant darkness as compared to the WT mice (3.897±0.781 vs 1.678±0.345, p=0.015). Total vessel area was similar in all groups suggesting no positive remodeling in this model. Our study demonstrates that disruption of Cry genes are associated with progression of neointimal formation in mouse flow cessation model. This further support the protective role of Cry genes in atherosclerosis.

ISO1-2 Manipulation of Intracellular Redox State using siRNA-mediated Knockdown of Thiol-metabolizing Pathways leads to Differential Modulation of Endothelial Nitric Oxide Pathways
Toru Sugiyama1,2, Yukio Hirata1, Thomas Michel3
1Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School, 2Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School

Cellular redox state is stringently maintained by thiol-based antioxidants to prevent the adverse consequences of generating excessive quantities of reactive oxygen species (ROS). The relative contributions of the thioredoxin (Trx) and glutathione/glutaredoxin systems to intracellular redox balance are incompletely understood, as are the consequences of altered thiol metabolism on eNOS and NO-dependent pathways in the endothelium. We designed duplex siRNA constructs to specifically “knock down” the expression of key thiol metabolizing enzymes in cultured aortic endothelial cells. siRNA-mediated knockdown of glutathione reductase (GR), cysteine Trx reductase (TrxR1), or mitochondrial Trx reductase (TrxR2) markedly suppressed VEGF-induced eNOS enzyme activity by 97 ± 2%, 85 ± 2%, or 101 ± 1% (n = 4, p < 0.01), and also decreased NO production by 83 ± 2%, 92 ± 2%, or 96 ± 2% (n = 4, p < 0.01). TrxR2 knockdown led to a marked increase in ROS production (39 ± 5% increase; n = 4, p < 0.01); this effect was entirely unaffected by siRNA-mediated knockdown of eNOS. In contrast, knockdown of GR or TrxR1 slightly but significantly increased ROS production by 38 ± 3% or 32 ± 5% (n = 4, p < 0.01); these effects were abrogated by simultaneous eNOS knockdown. TrxR1, but not GR or TrxR2, knockdown inhibited VEGF-induced phosphorylation of eNOS at the activating site Serine 1179 and Akt. These studies show that the differential regulation of thiol-metabolizing proteins has pleiotropic effects on endothelial function, leading to critical changes in oxidative and nitrosative stress pathways.

ISO1-3 Imidapril Prevents Contrast Media-Induced Nephropathy via Bradykinin Pathway
Jun-ichi Suzuki1, Mitsuaki Isobe1
1Department of Advanced Clinical Science and Therapeutics, University of Tokyo, Tokyo, Japan, 2Department of Cardiovascular Medicine, Tokyo Medical and Dental University

Background: Iodinated contrast media (CM) is used for diagnostic procedures; CM-induced nephropathy (CIN) affects the morbidity and mortality of patients. Although the renin angiotensin system (RAS) mediates the development of CIN, little is known about the evidence obtained from experimental models. Methods: We performed 5/6 subtotal nephrectomy (NTX) and administered CM (ipamidol) intravenously into the mice 4 weeks after NTX. We administered imidapril, an angiotensin converting enzyme (ACE) inhibitor, into the first group, TA606 which is an angiotensin II receptor blocker (ARB) into the second group, or imidapril plus a bradykinin B2 receptor antagonist (Hoe-140) into the third group daily. Results: Serum creatinine levels on day 28 were significantly elevated in the NTX group (n=8, 0.26±0.01mg/dl, p<0.05) compared to those in the non-NTX group (n=8, 0.13±0.01mg/dl). A day after CM injection, creatinine levels were additionally elevated in the non-treated NTX group (n=8, 0.48±0.07mg/dl, p<0.05) compared to that of CM injected NTX group. While imidapril treatment significantly suppressed creatinine levels (n=6, 0.34±0.04mg/dl, p<0.05) in the CM injected NTX mice, imidapril plus Hoe-140 treatment negated the suppression of creatinine levels (n=5, 0.43±0.07mg/dl, p=NS). TA606 treatment did not decrease creatinine levels (n=4, 0.47±0.06mg/dl, p=NS) in the CM injected NTX mice. These results indicate that ACEI treatment improves the renal function via bradykinin activation. Conclusion: ACEI treatment is useful for the prevention of CM-induced nephropathy because bradykinin pathway is critical to regulate CIN development.

ISO1-4 The Dual Regulatory Effects of Losartan in Angiotensin II-Receptor Mediated Signal Transduction in Vascular Smooth Muscle Cells
Yaqiong Wu3, Hidenori Takahashi1, Atsushi Numabe1, Yasuo Yanagi1, Yasuhito Tamaki1, Etsu Suzuki1, Makoto Araie2, Yoshihito Uehara3
1The Department of Cardiological Medicine, University of Tokyo, Tokyo, Japan, 2Department of Ophthalmology, University of Tokyo, Tokyo, Japan, 3Department of Clinical and Laboratory Medicine, Dokkyo University, Mibu, Tochigi, Japan, 4Health Service Center, University of Tokyo, Tokyo, Japan

Objectives: Rgs2 (regulator of G-protein signaling-2)-deficient mice exhibit persistent vascular constriction and severe hypertension, and genetic variations of RGS2 occur in hypertensive patients. Moreover we have known that RGS2 mRNA expression was up regulated by angiotensin II (Ang II) stimulation in vascular smooth muscle cells (VSMC). This study was to disclose the role of losartan in Ang II receptor mediated signal transduction through RGS2. Methods: VSMC were isolated from thoracic aorta of male Wistar rats and cells between passages 4 to 6 were used at semi-confluence growth stage. VSMC were incubated in losartan (500nM) or olmesartan (200nM) for different periods of time and cells were collected. RGS2 mRNA expression was performed by real-time quantitative reverse transcription polymerase chain reaction (QRT-PCR). Results: RGS2 mRNA levels peaked at 2 hours of Ang II (100nM) stimulation compared with control in VSMC. Olmesartan, type-1 receptor specific antagonist, completely inhibited this increase of RGS2. On the other hand, losartan (500nM) partially blocked the elevation of RGS2 and in the absence of Ang II losartan dose-dependently increased the RGS2mRNA expression. This effect of losartan was not influenced by the type-2 receptor antagonist (PD 123,319), and the agonist (CGP-42112A). Moreover, pretreatment of olmesartan abolished the increase in RGS2mRNA by losartan treatment. Conclusion: These results suggest that losartan uniquely blocks Ang II receptor mediated signal transduction through Ang II receptor antagonist action and a decrease of post-receptor signal transduction through the up-regulation of RGS2mRNA expression.
Objective: Left ventricular hypertrophy (LVH) is more common in hypertensive and obese people. β2-adrenoceptor (ADRB2) polymorphisms are closely linked to hypertension and obesity. We examined the relationships between ADRB1 and ADRB2 polymorphisms and LVH. Methods: In 215 normotensive, Japanese men, ADRB1 polymorphisms (Arg389Gly, Ser9Gly), ADRB2 polymorphisms (Arg16Gly, Glu27Glu), BMI, BP, heart rates (HR), total body fat mass, waist-to-hip ratio (W/H), plasma norepinephrine (NE) and ECG were measured. LVH was determined by ECG. Results: Twenty-four subjects (11.2%) showed LVH on ECG. Subjects with LVH had higher NE and HR compared to those without LVH (both P<.05). Distributions of Gly389 and Gly9 alleles of ADRB1 polymorphisms were 59.5% and 27.9%; >50% of subjects with LVH carried Gly389 and Gly9, especially homozygous. Subjects with Gly389 or Gly9 had higher frequencies of LVH, higher NE and HR (all P<.05), whereas BMI, fat-mass, W/H and BP were similar. Distributions of Gly16 and Gly27 alleles of ADRB2 polymorphisms were 74.4% and 11.2%. Twenty-two subjects (91.7%) with LVH carried Gly16, especially Gly16 homozygous, and 58.3% of subjects with LVH carried Gly27. Subjects with Gly16 had higher frequencies of LVH, and greater BMI, fat mass, W/H, BP, HR and NE compared to those without Gly16 allele (all P<.05). Conclusions: Subjects carrying Gly389 and Gly9 alleles of ADRB1 polymorphisms and Gly16 allele of ADRB2 polymorphisms had higher frequency of LVH accompanying high plasma NE. ADRB1 polymorphisms might relate to LVH through heightened sympathetic nerve activity, but ADRB2 polymorphisms might relate to LVH through obesity, hypertension and heightened sympathetic nerve activity.

Objective: Reproducibility of ambulatory blood pressure in hypertensive patients with treated and untreated conditions

Kazuko Eguchi1, Satoshi Hoshide1, Yoko Hoshide1, Shizukiyo Ishikawa1, Kazuuki Shimada1, Kazuomi Kario1

1Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan; 2Division of Community and Family Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan

Methods: We tested the reproducibility of ambulatory BP (ABP), BP variability, and the BP reduction in hypertensive patients. Methods: Forty-two hypertensives were enrolled, and ABP monitoring (ABPM) was performed 4 times in each patient: each twice in untreated and treated conditions. Morning BP was defined as the average of 2 hours after waking, and morning BP surge (MBPS) was defined as the difference of morning BP and lowest nighttime BP including trough, 2-hour BP before waking up, and 2-hour BP after sleep. The BP variability was evaluated by standard deviation (SD) and coefficient of variation (CV). The reproducibility was compared using the intraclass correlation coefficient (ICC) for agreements. Results: The ICC-agreements of awake, sleep, and 24-hour systolic BP (SBP) were 0.69, 0.75, and 0.77, and those of standard deviation (SD)/coefficient of variation (CV) were 0.36/0.38, 0.44/0.46, and 0.32/0.34. The ICC-agreement of morning SBP were 0.52, but that of MBPS were 0.18, 0.04, and 0.25, for sleep-trough, waking, and 2:00 after sleep SBP surge, respectively. When the MBPS was redefined based on actigraphy-defined waking time, the ICC-agreements of MBPS improved to 0.21, 0.16, and 0.25. The 24-hour BP-lowering effect correlated well between the two sets of ABPM before and after treatments (ICC-agreement 0.56). Conclusions: The reproducibility of ABP levels and BP variability were fairly good, and that of MBPS was fair when defined by actigraphy. The good reproducibility of BP reductions means that each single ABPM, before and after treatment, is acceptable for the assessment of drug efficacy.

Objective: Inappropriateness of Left Ventricular Hypertrophy influences BNP but not Influences Diastolic Filling in Untreated Hypertensive Patients

Akiyo Eguchi, Akihiro Goda, Shinji Nakao, Takeshi Tsujino, Misato Otsuka, Chikako Yoshida, Yoshiro Naito, Masaki Kawabata, Tooru Masayama

Cardiovascular Division, The Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan

Background: Echocardiographically-determined inappropriateness of left ventricular mass is an independent risk factor of cardiovascular events. Although left ventricular hypertrophy is associated with an increase in plasma brain natriuretic peptide level and a deteriorated left ventricular diastolic filling, it is unknown whether the inappropriateness of left ventricular mass affects these or not. Any hypertensive medication should affect LV geometry and function; therefore, this was studied in untreated hypertensive patients. Methods and Results: We studied 77 untreated hypertensive patients (49 males, 28 females, ages 59±12 years). Plasma brain natriuretic peptide level was measured in addition to routine echo Doppler indexes of left ventricular geometry and function. The appropriateness of LVM to cardiac workload was evaluated by the ratio of observed left ventricular mass to the value predicted for individual sex, stroke work, and height2.7 (dL/VMP/lVMP). Multivariate analysis showed plasma brain natriuretic peptide level increased with LVM but decreased when dL/VMP/lVMP increased. E/E ratio correlated not only with dL/VMP/lVMP but also with left ventricular mass index (r=0.30, p<0.05, r=0.37, p<0.05). However, when multiple stepwise regression analysis was performed, only left ventricular mass index was selected as a significant correlate of E/E ratio, indicating that inappropriateness of left ventricular mass does not affect E/E ratio in hypertensive patients. Conclusions: Brain natriuretic peptide levels are influenced not only by the degree of left ventricular hypertrophy but also by the inappropriateness of hypertrophy in untreated hypertensive patients. Diastolic filling is mostly affected by the degree of left ventricular hypertrophy, and not by the appropriateness of hypertrophy.
ISO2-9  Effects of valsartan and amlopidine on cardio-renal protection in Japanese hypertensive patients: The Valsartan Amlodipine Randomized Trial (VART)

Hiroya Narumi, Hiroyuki Takanaka, Satoshi Shindo, Keiko Nakayama, Miwa Fujita, Hiroshi Mizuma, Yoichi Kowabara, Jisei Komuro

Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Japan

Purpose: We assessed whether treatment with an angiotensin II type 1 receptor blocker (valsartan) or a calcium channel blocker (amlodipine) lowers cardiovascular events in essential hypertensive patients in Japan.

Methods: The Valsartan Amlodipine Randomized Trial (VART) was a prospective, randomized, open-label, 2-arm parallel comparative study. The initial dose was 80 mg/day valsartan or 5 mg/day amlopidine. These doses were increased to 160mg and 10mg, respectively, and β-blockers or α-blockers or diuretics were added if blood pressure was over 135/85. After the registration, patients were followed-up for cardiovascular events for 3 years and 123I-metaiodobenzylguanidine imaging (heart/mediastinum ratio/H/M ratio) for 1 year.

Results: 1,020 patients were enrolled and assigned to the two groups. At 36 months, both agents evenly lowered blood pressure to the target level (valsartan: from 158±20/94±13 mmHg to 134±14/80±13 mmHg; amlopidine: from 158±19 mmHg to 135±13/80±10 mmHg). At 24 months, we observed significant changes in the urinary albumin/creatinine ratio (UACR) in the valsartan group but not in the amlopidine group. In the valsartan group, H/M ratio at 6 year was significantly increased.

Conclusions: There were no significant differences in blood pressure level and the main outcome of cardiovascular events between the valsartan and amlopidine groups. However, we found significant improvements of UACR and cardiac sympathetic activity in the valsartan group. These results suggest that the effects of valsartan on heart and kidney were more beneficial than those of amlopidine in Japanese hypertensive patients.

ISO3-10  Relationship between baseline renal dysfunction and atherosclerotic events in patients with type 2 diabetes: Sub-analyses from the JPAD trial

Yoshihiko Saito1, Hisao Ogawa2, Takeshi Morimotob, Shiro Uemura3, Yasuhiko Aka1, Atsushi Kubo, Hirofumi Soejima2, Masafumi Nakayama1

1 1st Department of Internal Medicine, Nara Medical University, Kashihara, Japan, 2Department of Cardiology, Kansai University, Kansai, Japan, 3Center for Medical Education, Koya University Graduate School of Medicine

Diabetes is a powerful risk factor for cardiovascular events. Accumulating evidence indicates that intensive control of glucose control and blood pressure decreases cardiovascular events. However, effect of anti-platelet therapy with aspirin for primary prevention of cardiovascular events had not been elucidated. Recently we have accomplished the Japanese primary prevention of atherosclerosis with aspirin for diabetes (JPAD) trial last year, which is multicenter, prospective, randomized, open-label blinded-endpoint trial, and enrolled 2539 type2 diabetic patients without a history of atherosclerotic disease. Low-dose aspirin did not reduce primary end points of atherosclerotic events which includes fatal or nonfatal ischemic heart disease, fatal or nonfatal stroke including transient ischemic attack, and peripheral arterial disease. However, low-dose aspirin significantly (p<0.0037) reduced fatal stroke and acute myocardial infarction, and also significantly (p=0.047) reduced the atherosclerotic events in subgroup of patients aged 65 or older. Now we are undertaking some sub-analyses from the JPAD study. In the JPAD study, overall mean age was 65 10 years, 55% of patients were men. The median duration of diabetes was 70 years. The prevalence of hypertensive and overt diabetic nephropathy was 58% and 18%, respectively. The mean serum creatinine level was 0.8±0.3mg/dl. Prevalence of patients with estimated glomerular filtration rate (eGFR) <90ml/min/1.73m2, eGFR<90, 30<eGFR<60, eGFR<30 was 21%, 54%, 24%, and 20%, respectively. Effects of blood pressure and renal function on incidence of primary atherosclerotic events will be disclosed. Preliminary analysis confirmed that overt proteinuria is a strong risk for atherosclerotic events in the JPAD population.

ISO3-9  Relationship between lDd and atherosclerotic events in Japanese hypertensive patients: The CALBLOC study

Shin Takauchi1, Katsuhiro Ishii2, Fumiaki Nakamura3

1Department of Cardiology, Higashi Takarazuka Satoh Hospital, Takarazuka, Japan, 2Department of Cardiology, Iwasa Hospital, Iwasa, Japan, 3Department of Cardiology, Osaka Medical College, Takatsuki, Japan

Purpose: To investigate the effect of amlodipine on central blood pressure (BP) and arterial stiffness in mild to moderate essential hypertensives. Methods and Results: This 24 weeks, multi-center, open label, randomized, active drug comparative, parallel group study was designed as a noninferiority study. Eligible patients (n=200) were randomly assigned to receive benidipine (n=101) or losartan (n=99). Baseline radial artery tonometry noninvasive wave analysis device were used to derive central BP, pulse wave velocity (PWV) and augmentation index (AIx). Additionally, we measured the serum levels of hs-CRP, adiponectin, hs-RAGE, osteoprotegerin and procollagen I C-terminal propeptide (PICP) and calculated HOAMA index. No significant differences were found in the mean changes in central BP between two groups [±6.66 (systolic BP)/±10.70 (diastolic BP) mmHg in the benidipine group and -18.44/-11.79 mmHg in the losartan group; P=NS]. The mean changes in central aortic PWV and Alx were [-0.06±0.12 m/sec and (-.51±0.73 cm/sec) in the benidipine group and -0.02±0.12 m/sec and (-.42±0.12 m/sec) in losartan group (respectively; P=NS). There were no significant differences between two groups in the serum levels of metabolic and inflammatory biomarkers. Conclusion: These results suggested that benidipine was non-inferior to losartan to reduce central BP, brachial BP, and central aortic PWV, and also benidipine might have similar metabolic and inflammatory modulatory effects to losartan in mild to moderate essential hypertensives.

ISO3-11  Effects of azelnidipine on systemic hemodynamics and diastolic function in patients with hypertension. The CALBLOC study.

Shin Takauchi1, Katsuhiro Ishii2, Fumiaki Nakamura3

1Department of Cardiology, Higashi Takarazuka Satoh Hospital, Takarazuka, Japan, 2Department of Cardiology, Iwasa Hospital, Iwasa, Japan, 3Department of Cardiology, Osaka Medical College, Takatsuki, Japan

Objectives: This study aimed to compare the effect of benidipine (Calcium Channel Blocker) and losartan (Angiotensin Receptor Blocker) on central blood pressure (BP) and arterial stiffness in mild to moderate essential hypertensives. Methods and Results: This 24 weeks, multi-center, open label, randomized, active drug comparative, parallel group study was designed as a noninferiority study. Eligible patients (n=200) were randomly assigned to receive benidipine (n=101) or losartan (n=99). Baseline radial artery tonometry noninvasive wave analysis device were used to derive central BP, pulse wave velocity (PWV) and augmentation index (AIx). Additionally, we measured the serum levels of hs-CRP, adiponectin, hs-RAGE, osteoprotegerin and procollagen I C-terminal propeptide (PICP) and calculated HOAMA index. No significant differences were found in the mean changes in central BP between two groups [±6.66 (systolic BP)/±10.70 (diastolic BP) mmHg in the benidipine group and -18.44/-11.79 mmHg in the losartan group; P=NS]. The mean changes in central aortic PWV and Alx were [-0.06±0.12 m/sec and (-.51±0.73 cm/sec) in the benidipine group and -0.02±0.12 m/sec and (-.42±0.12 m/sec) in losartan group (respectively; P=NS). There were no significant differences between two groups in the serum levels of metabolic and inflammatory biomarkers. Conclusion: These results suggested that benidipine was non-inferior to losartan to reduce central BP, brachial BP, and central aortic PWV, and also benidipine might have similar metabolic and inflammatory modulatory effects to losartan in mild to moderate essential hypertensives.

ISO3-12  Relationship between baseline renal dysfunction and atherosclerotic events in patients with type 2 diabetes: Sub-analyses from the JPAD trial

1Department of Internal Medicine, Ibaraki Iseikai Hospital, Ibaraki, Japan, 2Department of Cardiology, Iwasuna Hospital, Gifu, Japan, 3Department of Cardiology, Minagawa Clinic, Gifu, Japan, 4Department of Cardiology, Hamamatsu Red Cross Hospital, Hamamatsu, Japan, 5Department of Cardiology, Kinki Central Hospital, Itami, Japan, 6Department of Internal Medicine, Toyota Koshi Hospital, Toyota, Japan, 7Minagawa Clinic, Gifu, Japan, 8Koto Clinic, Gifu, Japan

Diastolic heart failure forms an important subset with increasing incidence and prevalence in patients with hypertension, and risk of all cause mortality and cardiovascular events is significantly increased. Although the beneficial role of RAA$ blockad$e has been well established, controversies continue to surround the efficacy of calcium antagonists for diastolic heart failure. Unlike other dihydropyridine calcium blockers, azelnidipine has the unique feature that has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate. The aim of the CALBLOC study is to investigate the effect of azelnidipine on blood pressure and diastolic failure in patients with hypertension. 246 hypertensive patients with diastolic heart failure were entered in this trial. Hemodynamic parameters, laboratory data (including BNP, hs-CRP), and echocardiographic parameters of diastolic function (E/A, DT, C, and e') were assessed at baseline and 6 months after administration of azelnidipine. 78 patients were switched from amlodipine to azelnidipine. Blood pressure (160±17mmHg to 138±11mmHg) and heart rate (87±14bpm to 78±14 bpm) were significantly decreased. Although BNP and other biomarkers were not significantly changed, diastolic function (E' (6.0±1.4 to 6.5±1.2)) was significantly improved. In the patients that were switched from amlodipine, blood pressure and heart rate were significantly decreased, and there was tendency to improve diastolic function. These data suggested that azelnidipine might have cardioprotective effect on hypertensive patients with diastolic heart failure along blood pressure and heart rate lowering effect.
ISO3-13  Docosahexaenoic Acid or Olive Oil Supplementation on Blood Pressure and Serum Lipids in Scottish Men with Mild Hypertension and Hypercholesterolaemia

Miki Sagara¹, Takashi Taguchi², Mari Mori³, Yukio Yamori⁴
¹Laboratory of Preventive Nutritional Medicine, Research Institute for Production Development, Kyoto, Japan, ²Institute for World Health Development, Mukogawa Woman’s University, Hyogo, Japan

The objective of this study was to investigate the effects of daily supplementation with docosahexaenoic acid (DHA) on blood pressure (BP), heart rate (HR) and serum lipids in fifty-six middle-aged Scottish men with mild hypertension (systolic BP (SBP) ≥ 130 mmHg) and mild hypercholesterolemia (total cholesterol (TC) ≥ 220 mg/dl). Methods: Subjects were assigned a five-week double blind placebo-controlled dietary supplementation with either 2g of DHA powder or active placebo (containing 2g olive oil powder) daily. Supplements were administered incorporated in bread rolls (2 bread rolls supplied one-day dose). Health survey was carried out twice before and after the intervention and 24-hour urine samples and fasting blood were analyzed according to WHO-CARDIAC study protocol. Results: The percent composition of DHA in plasma phospholipids among DHA supplemented group (DHA group) increased significantly from 1±0.4% at the beginning of the study to 3.5±0.9% (p<0.001) at the end of five-week intervention. In the DHA group, significant changes were observed in SBP (5.8% decrease, p<0.001), diastolic BP (DBP) (3.7% decrease, p<0.01) and HR (7.5% decrease, p<0.05). The increment of DHA was related significantly with BP reduction. There was no significant decrease in SBP and DBP levels or changes in HR in the placebo group before and after intervention period. High density lipoprotein cholesterol (HDL-C) increased significantly and TC/HDL-C and non HDL-C/HDL-C ratios decreased significantly in both groups. Conclusion: DHA supplementation (2g/day) reduced BP and HR in mildly hypertensive, hyper-cholesterolemic Scottish men. (We acknowledge the great cooperates of Drs. NJELEKELA, M., ARMITAGE, L., BIRT N., and BIRT, C.)

ISO3-14  Undetected Hypertension: Related factors and long term follow up in a representative Japanese cohort, NIPPON DATA80

Tanvir Chowdhury Turin¹, Katsuyuki Miura¹, Nahid Rumana¹, Yasuyuki Nakamura¹, Yoshikuni Kita¹, Aya Higashiyama¹, Sayaka Kadowaki¹, Tomonori Okamura¹, Akira Okayama¹, Hirotsugu Ueshima¹
¹Department of Health Science, Shiga University of Medical Science, Japan, ²Department of Cardiovascular Epidemiology, Kyoto Women’s University, Kyoto, Japan, ³Department of Preventive Cardiology, National Cardiovascular Center, Osaka, Japan, ⁴The First Institute for Health Promotion and Health Care, Tokyo, Japan.

Background: It is important to audit the prevalence of undetected hypertension at the community level to identify related factors and long-term outcome to initiate avenues for improvement in population level hypertension control. Methods: We analyzed data from the NIPPON DATA80 consisting 8002 participants aged 30-65. As the baseline was conducted in the 1980, thus hypertension was defined as SBP≥160 and/or DBP≥95 and/or being on antihypertensive medication (JNC-2). We used multivariate logistic regression to identify independent predictors of undetected hypertension both in relation to normotensive and detected hypertensive. The multivariate-adjusted hazard ratio (HR) of cardiovascular disease (CVD) mortality was estimated for undetected hypertension in reference to both normotensive as well as detected hypertensive. The multivariate-adjusted hazard ratio (HR) of cardiovascular disease (CVD) mortality was estimated for undetected hypertension in reference to both normotensive as well as detected hypertensive by Cox proportional hazard model. Results: We estimated that 23.9% of the population had hypertension and 29.9% of them were undetected of their hypertension problem. Increasing age, being male, having history of heart disease, being obese and having drinking habit were independently associated with undetected hypertension in relation to normotensive. The multivariate adjusted HR for CVD for undetected hypertension was 2.42 (95%CI:1.76-3.31) in reference to normotensive. In the comparison between detected and undetected hypertension; being younger, being male, not having history of stroke, heart disease or diabetes, and having lower BMI were independently associated with undetected hypertension. Though statistically insignificant, undetected hypertensive had 26% more chance of CVD death than participants with detected hypertension. Conclusion: These results points towards the importance of detecting hypertension vigorously in the community level which will have positive impact on long-term cardiovascular outcome.
**Objective:** The binding properties of renin and prorenin to (P)RR were investigated by kinetic study in BIACore assay system and thus, to elucidate the possibility of multiple binding sites in the receptor for renin/prorenin.

**Methods:** The (P)RR (35 kDa) was expressed in a cell free in vitro system and purified by affinity chromatography using His Trap column. A polyclonal antibody was prepared against a region close to the transmembrane part of the receptor (E1014IGKRYGDSDFQRK)3, purified and immobilized on the CM5 sensor chip. The receptor bound to the immobilized antibody showed binding of human renin, prorenin (0.1-2.0 nM) and the peptides such as "KKRLFDYV/EY"2, the hinge "QQYVLKEDVF/V"2 from renin and LPTDT4, LPTDTTTF4, L3PTDTTTF4, L2PTDTTFFRFLKR4 and the decoy R3FLKRPSMT4 from prorenin.

**Results:** The dissociation constants (Kd) for the human renin, prorenin, decy and hinge peptides bound to the (P)RR were 4.4, 1.2, 3.5 and 17 nM, respectively, whereas these values for L3PTDT4, L3PTDTTTF4, L2PTDTTFFRFLKR4 were 3.2 x 10^-5, 52, 76 and 4.1 x 10^-5 nM, respectively. Among these, peptides containing 1KFLKR9 sequence and hinge showed more stable complex as reflected from their Kd's. Both decoy and hinge peptides reduced the resonance signal for the binding of human prorenin and renin to (P)RR.

**Conclusion:** The decoy had higher binding affinity (1/Kd) than the hinge and is only conserved in prorenin whereas the hinge is present in renin and prorenin molecules. These indicate (P)RR has at least two binding sites. Thus, this study is the first evidence of multiple binding sites in (P)RR.

**Acknowledgments:** The authors wish to express their sincere thanks to Dr. T. Iwata, JASRI and Dr. S. Hara, WPI Research Institute for their kind help and suggestions during this work. The authors would also like to thank Dr. J. P. Ito (Johns Hopkins University, USA) for providing the antibody against a region close to the transmembrane part of the receptor.

**References:**


---

**In vitro inhibition of the activity of mature renin and (pro)renin receptor-bound activated prorenin by aliskiren**

Kazal Boron Biswas1, AHM Nurun Nabi2, Akio Ebihara1, Yoshihisa Arai1, Tsutomu Nakagawa1, Atsuhiro Ichihara1, Tadashi Inagami1, Fumiaki Suzuki2

1Unit Grad Sch Agri Sci, Gifu University, Japan, 2Fac Appl Biol Sci, Gifu University, Japan

**Objective:** Aliskiren, a nonpeptidic orally active direct inhibitor of renin, has been approved as an antihypertensive agent. In this study, the effects of aliskiren on the activities of human (pro)renin receptor [h(P)RR] bound active renin and prorenin were tested to evaluate its inhibitory ability on the circulating and tissue-specific aldosterone synthesis.

**Methods:** Plasmid pCDNA3 harboring h(P)RR lacking transmembrane sequence was ligated with a vector, pGEX. Thus, the receptor was expressed in a cell free in vitro system based on wheat germ lysate. Chinese hamster ovary cell lines were maintained for the preparation of human mature renin and prorenin. To elucidate the possibility of multiple binding sites in the receptor for renin/prorenin. The expression level of CYP11B2 in Dahl salt-sensitive rat as associated with cardiovascular injury. We examined the different response of the adrenal aldosterone biosynthesis to salt in Dahl salt-sensitive rat as compared to salt-resistant rats. Methods and Results: Dahl salt-sensitive (S), salt-resistant (R) rats were fed a high-salt (8% NaCl) or a normal-salt (1% NaCl) diet from 5th to 11th weeks of age. The expression level of CYP11B2 (aldosterone synthase) was determined by immunoblotchemistry and Q-PCR. Steroid metabolites in adrenal glands, plasma, and left ventricle were measured by the liquid chromatography- tandem mass spectrometry analysis.

**Previous studies have shown that plasma renin activity is lower in normal salt-fed S than in normal salt-fed R. Consistently, the adrenal CYP11B2 expression was lower in S than in R. Accordingly, adrenal aldosterone levels, as well as plasma and cardiac aldosterone levels, were significantly lower in normal salt-fed S than normal salt-fed R. At the end of high salt intake, the adrenal CYP11B2 expression was equally suppressed in both R and S. The adrenal, plasma and myocardial aldosterone levels were markedly suppressed in S. As a consequence, adrenal, plasma, cardiac aldosterone were 19-, 68-, 51-fold higher in S than in R. The plasma and cardiac aldosterone in high salt-fed S became undetectable after bilateral adrenalectomy. Conclusions: These results suggested that CYP11B2-independent aldosterone synthesis emerged in S under a high salt intake. This abnormality may play a pathogenic role for the development of cardiovascular disease.
RhoA/rho-kinase pathway facilitates rat aortic contraction through increases in binding affinities of endothelin-1 and noradrenaline to their receptors

Takaki Yamamura1, Tetsuya Sakajiri1, Haruo Abe2, Kyusa Abe1, Takako Sawada1

1Department of Food and Nutrition, Morioka Junior College, Morioka College, Iwate, Japan, 2Nutrition Section, Totinoki Hospital, Tochigi, Japan

Endothelin-1 (ET-1) and noradrenaline (NA) induce potent contraction of vascular smooth muscle which is closely related to hypertension. Smooth muscle contraction is regulated by [Ca$^{2+}$]i and Ca$^{2+}$ sensitivity of contractile elements. It is known that activation of the rhoA (a small GTP-binding protein)/rho-kinase pathway inactivates MLC phosphatase by phosphorylation of its myosin-binding subunit, resulting in increasing MLC phosphorylation leading to enhancement of muscle contraction at a given intracellular Ca$^{2+}$ concentration. This study found new functions of the rhoA/rho-kinase pathway.

In rat isolated aorta without endothelium, the ET-1 (100nM)- or NA (1μM)-induced contraction was incompletely inhibited by the endothelinA receptor antagonist BQ-123 (1μM) or the α1-adrenergic receptor antagonist prazosin (0.001μM), respectively. The contractions induced by these agonists were also incompletely inhibited by the rho-kinase inhibitor Y-27632 (1μM). However, combination of Y-27632 (1μM) with BQ-123 (1μM) or prazosin (0.001μM) was rapidly and completely inhibited the ET-1 (100nM)- or NA (1μM)-induced contraction, respectively. Combination of the L-type Ca$^{2+}$ channel blocker verapamil (10μM) with Y-27632 (1μM) completely and synergistically inhibited the ET-1-induced contraction. For inhibition of the ET-1-induced contraction, combination of the MLCK inhibitor wortmannin (10μM) with BQ-123 (1μM) did not show any synergistic effects. These results suggest that activation of the rhoA/rho-kinase pathway increases binding affinities of ET-1 and NA to their receptors, the pathway is also involved in the uptake of Ca$^{2+}$, and it does not affect the activation of MLCK.

Left Ventricle Compensates for Acute Mild and Moderate increase of Pulmonary artery pressure by Increased Torsion

Eun-Joo Cho1, Jae-Hyung Kim1, Panupong Jiamsripong2, Anna-M Calleja2, Mohsen-A Alharthi1, Eileen-M McMahon2, Krishnaswamy Chandrasekaran2, Bijoy-K Khandheria2, Marek Belohlavek2

1Department of Internal Medicine, Division of Cardiology, Catholic University of Korea, Seoul, Korea, 2Translational Ultrasound Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona

Background - The right ventricle (RV) and left ventricle (LV) share the interventricular septum (IVS), which mechanically transmits interventricular pressure gradients. With increased pulmonary artery pressure (PAP), 1) the IVS straightens with consequent LV end-diastolic volume decreases, and 2) RV stroke volume decreases. However, whether the acute mild to moderate increase of PAP affect LV function is controversial. The aim of this study was to investigate changes of LV torsion magnitude response to decrease of LV end-diastolic volume and RV stroke volume during graded acute elevation in PAP.

Methods - In 14 open-chest pigs (43±4 kg) with preserved pericardium, acute mild (>35 and <50 mmHg) and moderate (>50 and <60 mmHg) increase of PAP were induced by constriction of the pulmonary artery. Hemodynamic parameters and LV torsion were evaluated at each condition.

Results - At baseline and during mild and moderate increase of PAP, the mean RV systolic pressure was 31.0±4.3, 41.1±2.7, and 52.7±3.4 mmHg, respectively. LV torsion magnitudes increased from baseline to mild and moderate increase of PAP (2.7±0.9, 3.4±0.7, 3.7±1.0 degree/cm, respectively, P=0.029). LV systolic torsion magnitude correlated with RV systolic pressure (r=0.428, P=0.009). In multiple regression analysis, LV systolic eccentricity index was independently related to an increase in LV torsion magnitude (r=0.548, P=0.001). Conclusion - Consequent IVS displacement towards the LV free wall associated with acutely increasing pulmonary artery pressure associated with an increase in LV torsion magnitude. Increase of LV torsion magnitude reflects an LV functional compensatory mechanism during acutely increasing PAP.
**IP02-007**

Epigeneic transcriptional repression of the human CYP11B2 gene

Masashi Demura, Takashi Yoneda, Hironari Karashima, Yoshio Takeda
Division of Endocrinology and Hypertension, Kanazawa University, Kanazawa, Japan

**PURPOSE:** The Ad1/cAMP response element (CRE) and Ad5 have been shown to play a crucial role in the transcriptional regulation of CYP11B2. These cis-acting elements contain CpG dinucleotides, which are target sites for DNA methylation. Our objective was to elucidate effects of CpG methylation on human CYP11B2 expression.

**METHODS:** Human adrenal corticoal H295R cell lines were cultured to analyze endogenous CYP11B2 expression, transcription factor complex formation, and promoter activity.

**RESULTS:** We found that CpG dinucleotides of the Ad1/CRE and Ad5 were largely unmethylated in tissues from aldosterone-producing adenoma and adjacent adrenal gland, compared to leukocytes. Analysis of the CYP11B2 promoter fused to a reporter gene showed that CpG dinucleotide methylation within its promoter completely abolished CYP11B2 promoter activities, which were stimulated by angiotensin II, KCL, and cAMP. Promoter constructs with partial CpG methylation responded weakly to these stimuli, suggesting that the CYP11B2 promoter activity was dependent upon CpG methylation. NoShift transcriptional factor assays demonstrated that CpG methylation significantly decreased CREB binding to the Ad1/CRE by 90% and NURR1 binding to the Ad5 by half in nuclear extracts from H295R cells. Likewise, CpG methylation significantly increased methyl CpG binding protein 2 (Mecp2) binding to the Ad1/CRE in vitro. Chromatin immunoprecipitation-immunostaining PCR showed that Mecp2 interacted strongly with methylated Ad1/CRE and weakly with methylated Ad5 in vivo.

**CONCLUSIONS:** Taken together, CpG methylation repressed human CYP11B2 promoter activity by decreasing binding of activators as CREB and NURR1 and increasing binding of a repressor(s) as Mecp2. This is the first demonstration of methylation-dependent regulation of CYP11B2.

**IP02-008**

ChREBP promotes ERK phosphorylation through the crosstalk between cyclic mechanical strain and high glucose in rat mesangial cells

Junichi Yatake, 1,2 Midori Yatabe, 1,2 Hiroonobu Sanada, 1,2 Tuyoshi Watanabe
1Division of Health Science Research, Fukushima Welfare Federation of Agricultural Cooperatives, Fukushima, Japan, 2Department of Pharmacology, Fukushima Medical University School of Medicine, Fukushima, Japan, 3Department of Nephrology, Hypertension, Diabetology, Endocrinology and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan

**MAP kinase activation caused by hypertension and hyperglycemia is known to play a pivotal role in the development of glomerular dysfunction by inducing mesangial proliferation. To elucidate the mechanism of strain and glucose stimulation leading to ERK phosphorylation, we focused on a recently-identified transcription factor, carbohydrate-responsive element-binding protein (ChREBP). This study was carried out to determine if ChREBP is involved in the signal transduction from glucose and mechanical stimulation leading to ERK phosphorylation in mesangial cells. When cyclic mechanical strain was applied to rat mesangial cells, ChREBP transcripts increased in a time- and elongation strength-dependent manner. From the results of chromatin immunoprecipitation-guided ligation and selection assay, a MAP kinase-related gene, MPI, emerged as a possible target gene. Electromobility Shift Assay using the MPI promoter and crude nuclear extract from glucose-stimulated rat mesangial cells showed an increase in the signal shift. The mRNA expression of MPI was increased in a high-glucose condition compared to low-glucose. When mesangial cells were subjected to mechanical stretch and then cultured in low or high glucose medium for 24 hours, the ratio of p-ERK to total ERK were elevated the most in the stretch plus high glucose group. In summary, stretch-induced ChREBP transcription and ChREBP nuclear translocation in response to glucose, leading to MPI expression and ERK activation, may be one of the mechanisms linking mechanical stress and high glucose. ChREBP and MPI may play a significant role in the pathophysiology of renal damage caused by hypertension and hyperglycemia.

**IP02-009**

Anti-Oxidant or potassium diet could reverse salt-sensitive hypertension via WNK4 regulation

Shengyu Mu, 1 Tatsuo Shimosawa, 1 Sayoko Ogura, 2 Fumiko Mori, 1 Hong Wang, 1 Yuzaburo Uetake, 1 Toshiro Fujita 1
1Department of Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan, 2Department of Clinical Laboratory, University of Tokyo, Tokyo, Japan

**Recent reports showed that WNK kinases play important roles in the regulation of sodium transport in the distal nephron, therefore regulate the blood pressure. In this experiment we showed that WNK4 expression enhanced during anti-oxidant or potassium treatment, which could reverse the sodium-sensitive hypertension in Dahl S rats. We use 6 weeks old Dahl salt-resistance and salt-sensitive rats, treated with High salt diet, or high salt-potassium diet for 2 or 4 weeks. Then measured direct blood pressure and evaluate WNK4 expression by real-time RT-PCR. Sodium channel expression was checked by western blot. After that we use anti-oxidant medicine Tempol treated to DS rats with HS diet for 2 weeks, direct blood pressure was measured by catheter, WNK4 expression was evaluated by quantitative RT-PCR. After 2 weeks, young age rats showed no differences in blood pressure. However WNK4 expression in DR rats rose about 30 percent after HS diet which DS rats did not. During HS+potassium diet, WNK4 expression raised in both groups. After 4 weeks, DS rats with HS diet showed obvious high blood pressure, however all DR rats and DS with HS+potassium diet rats showed normal. Also, DS rats treated with HS diet and Tempol for 2 weeks increased WNK4 expression, then prevent the sodium-sensitive hypertension. In this study we found that WNK4 regulation might be one of the reasons why DS rats could easily cause salt-sensitive hypertension. Also, this sensitivity could be reduced by anti-oxidant or potassium treatment.**

**IP02-010**

Oxidative stress in glucocorticoid-induced MR activation

Hong Wang, Tatsuo Shimosawa, Sayoko Ogura, Fumiko Mori, Yuzaburo Uetake, Shengyu Mu, Hiromitsu Matsui, Toshiro Fujita
Department of Medicine, University of Tokyo, Tokyo, Japan

**We have reported the role of ROS related mineralocorticoid receptor (MR) activation in Ang II induced cardiac dysfunction. In order to further investigate the underlying mechanism how MR was activated and caused cardiac dysfunction, we studied MR activation in cardiac muscle cells. Under high oxidative state (by high glucose, poronide loading, or mechanical stretch), MR is translocated into nucleus not only by aldosterone but also by corticosterone. Also, when MR activity is monitored by MR-dependent gene expression, MR is activated by corticosterone only under high oxidative state. Combined with former reports, MR in the heart in 11b HS2D is absent can be activated by corticosterone and that MR activation causes abnormal calcium handling in the heart results in diastolic dysfunction.**

The 32nd Annual Scientific Meeting of the Japanese Society of Hypertension 367
Urinary Neutrophil Gelatinase-Associated Lipocalin in Diabetic Nephropathy and Hypertension and Its Response to Angiotensin Receptor Blocker

Kiyoshi Mori¹, Masashi Mukoyama¹, Masato Kasahara¹, Noriko Satoh³, Takashige Kuwabara¹, Yoko Saito¹, Hiduki Yokoi¹, Hirotaka Imamaki¹, Yoshiiya Ogawa¹, Tomoko Kawanishi¹, Akira Sugawara¹, Kazuwa Nakao³

1Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Clinical Research Institute for Endocrine Metabolic Disease, Kyoto Medical Center, Kyoto, Japan, ³Department of Nephrology, Kyoto Medical Center, Kyoto, Japan


[Methods and Results] Urinary Ngal levels were highly elevated in two models of DN: A-ZIP/F-1 lipoatrophic diabetes (exhibiting insulin resistance and nephrotic range proteinuria) and STZ diabetic mice (with insulin deficiency and microalbuminuria). In STZ mice, reabsorption of labeled-Ngal was reduced by half and its urinary excretion was highly increased. Treatment of STZ mice with candesartan largely suppressed elevation of urinary Ngal concentrations. In hypertensive patients with diabetes or obesity, administration of ARB (candesartan, olmesartan or telmisartan) caused reduction of blood pressure, and urinary Ngal and albumin excretion after 3 months. In these patients, urinary Ngal and albumin levels were not significantly correlated, suggesting that these two are independent clinical parameters.

[Conclusion] Urinary excretion of Ngal was increased mainly by tubular reabsorption impairment in DN. Furthermore, urinary Ngal level in DN and hypertension was significantly decreased by ARB treatment, suggesting that it may serve as a new biomarker for diabetes- or hypertension-related nephropathy.
IP03-012 Utility and feasibility of a new programmable home blood pressure monitoring device for the assessment of night-time blood pressure.

Tomokazu Ishigami, Hisako Ushio, Naomi Araki, Shintaro Minegishi, Koichi Tamura, Yoshiyuki Toy, Kazuaki Uchino, Osamu Tochikubo, Satoshi Umemura

Department of Medicine and Cardiological Medicine, Yokohama City University Graduate School of Medicine

BACKGROUND: Recent evidence indicates that both ambulatory blood pressure monitoring and home blood pressure monitoring are more useful than the measurement of office blood pressure for evaluating cardiovascular risks in subjects with hypertension. The major advantage of ambulatory blood pressure monitoring over home blood pressure monitoring is the ability to measure nighttime blood pressure and ambulatory blood pressure during the day. A newly developed, programmable home blood pressure monitoring device (HEM-5041, OMRON, Kyoto, Japan) can record blood pressure up to 350 times and measure nighttime blood pressure automatically up to twenty times.

METHODS: To validate the utility, feasibility and safety of this device, we measured blood pressure by home blood pressure monitoring using HEM-5041 and by ambulatory blood pressure monitoring and compared the values in healthy volunteers. RESULTS: As compared with ambulatory blood pressure monitoring, daytime blood pressures, coefficients of variation for systolic blood pressure, diastolic blood pressure, and pulse rate, and the percentage of falls in these variables were significantly lower with home blood pressure monitoring. However, nighttime blood pressure did not significantly differ between home blood pressure monitoring and ambulatory blood pressure monitoring. The results of a questionnaire survey indicated that the subjects were more comfortable when blood pressure measured by home blood pressure monitoring than by ambulatory blood pressure monitoring, whereas the quality of sleep was similar. CONCLUSIONS: Our results suggest that HEM-5041 is useful for evaluating nighttime blood pressures as well as nighttime blood pressure falls, without causing clinically significant discomfort.

IP03-013 Hypertension Risk and Atherosclerosis parameter CAVI in Japan and Central EU

Tomoyuki Yambe1, Petr Dobsky2
1Tohoku University, Sendai, Japan, 2St. Anna University Hospital Brno, Czech Republic

Hypertension, obesity and metabolic syndrome as the cardiovascular risk is important problem not only in Japan, but also in European countries. In European Union (EU), the importance of obesity was increased more and more in every countries, when we consider the preventive medicine. Among E.U., worst group of obesity is Marta and Russia, and Czech, Lithuania, Belgium were in the second group. Thus, we evaluated the atherosclerosis in Czech, which exist in the center of E.U., as the typical example of the E.U. residence. For the evaluation of the atherosclerosis, the relationship between the Cardio Ankle Vascular Index (CAVI) and aging of the Japanese and Czech people was compared in this study. 157 Healthy Subjects 36 DM patients, and 58 hypertensive subjects were evaluated in the Brno, Czech, and compared with Japanese data. As the results, CAVI is increasing intentionally according to aging in also as for the Czech people, and Japanese people. Increase Rate of CAVI according to the Aging was larger, compared with Japanese data. Therefore, it was shown that the Czech people have a quick advance of the arteriosclerosis according to aging compared with Japanese people. In the analysis of an arteriosclerosis risk, it has become clear that existence of diabetes etc. has contributed to increase of CAVI greatly etc. Unfortunately, criteria of obesity and metabolic syndrome are different that comparison is a little bit difficult. Development of atherosclerosis research may be desired for the people's health in Japan and E.U. health.

IP03-014 The difference of therapeutic impact according to antihypertensive medicine to central aortic pressure.

Tomoo Furumoto1, Satoshi Fuji1, Hiroyuki Tsutsumi2
1Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 2Department of Molecular and Cellular Pathobiology and Therapeutics, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan

Objectives: After the publication of ASCOT-CAFE study, central aortic pressure (cAP) has been focused as a new risk factor or new therapeutic marker of cardiovascular disease. So we examined the effect of antihypertensive medicine to cAP in Japanese hypertensives. Methods: We enrolled hypertensive outpatients (n=135) who received Ca antagonist (n=32) or renin-angiotensin system (RAS) inhibitor. Objectives were divided into 3 groups according to medicine: Ca antagonist alone group (n=30), RAS inhibitor alone group (n=48) and Ca and RAS combination therapy group (n=57). Results: Systolic and diastolic blood pressures were equal in all groups. cAP of Ca alone and RAS inhibitor alone was not different. But cAP of combination group was about 5mmHg lower than other 2 groups and brain natriuretic peptide was about 35 pg/ml reduced only in combination group. Moreover, 42% patients in combination group cAP were lower than systolic BP. On the other hand about 80% patient cAP were not good control in rest 2 groups. In this study cardiac index and was reduced by using RAS inhibitor. Total peripheral resistance was reduced by Ca antagonist. And RAS inhibitor may be able to reduce oxidant stress and inflammation. These effects may act synergically and reduce cAP in combination group. Conclusion: This study suggest that combination therapy of Ca antagonist and RAS inhibitor can reduce central aortic pressure in Japanese hypertensives. The elucidation of mechanism and best combination need furthermore investigation.

IP03-015 Constructing Prediction Models for the Risk of New-onset Hypertension from a Prospective Cohort

Kuo-Liong Chien1, Hsu Hsiu-Ching2, Su Ta-Chen2, Chang Wei-Tien1, Chen Pei-Chun3, Sung Fung-Chang4, Chen Ming-Fong2, Lee Yuan-Teh5
1Institute of Preventive Medicine, National Taiwan University, Taipei, Taiwan, 2Department of Internal Medicine, National Taiwan University Hospital, 3Department of Emergency Medicine, National Taiwan University Hospital, 4The Chinese Medical University Hospital

We aimed to propose prediction models for new-onset hypertension using a community-based cohort of middle and elderly ethnic Chinese in Taiwan. Among 2506 individuals (50.8% women) who were not hypertensive at the baseline (1990-91), 1029 cases of new-onset hypertension developed during a median of 6.15 (interquartile range, 4.04-9.02) years of follow-up. The multivariate Weibull model was applied to construct two prediction models. In the clinical model, gender (2 points), age (8 points), body mass index (10 points), systolic blood pressure (19 points), and diastolic blood pressure (7 points) were assigned. The biochemical measures, including white blood cell count (3 points), fasting glucose (1 point), uric acid (3 points), additional to clinical variables, were constructed. The areas under the receiver operating characteristic (ROC) curves were 0.732 (95% confidence interval [CI], 0.712 - 0.752) for the points-based clinical model and 0.735 (95% CI, 0.715 - 0.755) for the points-based biochemical model. The points-based clinical model had a similar net reclassification improvement as the coefficient-based clinical model (P=0.30), and had a higher improvement than the points-based biochemical model (P=0.015). These prediction models outperformed available models, including John Hopkins and Framingham models, to predict hypertension risk. In conclusion, the points-based clinical model could be considered as the first step to identify high-risk populations for hypertension.
IP03-016  Ambulatory Blood Pressure monitoring by a dual home BP (HBPM)/ABP Monitoring Device -Microlife WatchBP O3-

Joji Ishikawa1, Efthimia Nasothimiou1, Nikos Karpettas2, Seth Feltheimer1, Scott McDoniel1, Joseph Schwartz1, George Stergiou2, Thomas Pickering1

1Center for Behavioral Cardiovascular Health, Columbia University Medical Center, NY, USA, 2Hypertension Center, Third University, Department of Medicine, Sotiria Hospital, Athens, Greece.

Background: We evaluated whether ambulatory blood pressure (ABP) using a dual-mode oscillometric device that performs both home BP (HBPM) and ABP monitoring (ABPM) is related to ABP measured by a conventional ABPM device in addition to HBPM.

Methods: Hypertensive patients performed HBPM (Microlife WatchBP Home), and 24-hr ABPM using a dual HBPM/ABPM device (Microlife WatchBP O3) and a conventional ABPM device (SpaceLabs 90207) within 4 weeks.

Results: There was no significant difference between awake systolic BP (SBP) by the conventional ABPM (138±16 mmHg, P=0.39) vs. awake SBP by the dual HBPM/ABPM device (139±16 mmHg, P=0.23) or vs. home BP (SBP 140±17 mmHg, P=0.23) (N=52). There was no significant difference between awake diastolic BP (DBP) by the conventional ABPM (81±13 mmHg) vs. home DBP (82±11 mmHg, P=0.29), but was vs. awake DBP by the dual HBPM/ABPM device (83±11 mmHg, P=0.019). In a multiple linear regression analysis, awake SBP by the dual HBPM/ABPM device (B=0.40, P=0.002) was a significant predictor of awake SBP by conventional ABPM, independently of home SBP (B=0.45, P=0.001) and office SBP (P=0.25). In the parallel analysis of DBP, awake DBP by the dual HBPM/ABPM device (B=0.55, P=0.001) was also a significant predictor of awake DBP by conventional ABPM, independently of home DBP (B=0.49, P=0.002) and office DBP (P=0.87).

Conclusion: These preliminary data indicate that home BP and ambulatory BP measured by the dual HBPM/ABPM device are each independently predictive, controlling for the other and office BP, of awake BP measured using a conventional ABPM device.

IP03-017  Automatic Office Blood Pressure Measurement without doctors or nurses present is Predictive of Ambulatory Blood Pressure-Microlife WatchBP Office-

Joji Ishikawa1, Efthimia Nasothimiou1, Nikos Karpettas2, Seth Feltheimer1, Scott McDoniel4, Joseph Schwartz1, George Stergiou2, Thomas Pickering1

1Center for Behavioral Cardiovascular Health, Columbia University Medical Center, NY, USA, 2Hypertension Center, Third University, Department of Medicine, Sotiria Hospital, Athens, Greece, 3Department of Internal Medicine, Columbia University Medical Center, NY, USA, 4Microlife Medical Home Solutions, Inc. Golden, CO, USA

Backgrounds: We evaluated whether automatic office blood pressure (OBP), in which the readings were taken without doctors or nurses, is more strongly related to ambulatory blood pressure (ABP) than is OBP measured by mercury sphygmomanometer.

Methods: Hypertensive patients had their OBP measured using an automatic upper arm oscillometric monitor (Auto; Microlife WatchBP Office) and by mercury sphygmomanometer (Sphy), in 3 clinic visits. Between the visits, ABP monitoring (SpaceLabs 90207) and home BP monitoring (Microlife WatchBP Home) were also performed.

Results: Both Auto OSBP and Sphy OSBP were significantly correlated with 24-hr SBP (Auto OSBP, r=0.69; Sphy OSBP, r=0.68) and awake SBP (Auto OSBP, r=0.67; Sphy OSBP, r=0.64) (all P<0.001). The same was true for diastolic BP. In multiple linear regression analysis including Auto OSBP and Sphy OSBP together, Auto OSBP was more strongly related with awake SBP (B=0.54, P=0.023) and 24-hr SBP (B=0.51, P=0.024) than was Sphy OSBP (both P<0.05). Even when home SBP was included in the model, Auto OSBP was a significant predictor of awake SBP (B=0.36, P=0.046) and 24-hr SBP (B=0.33, P=0.049). In parallel analyses for DBP, Auto ODBP was also more strongly related to awake DBP and 24-hr DBP than was Sphy ODBP.

Conclusion: These preliminary data indicate that office BP measured without doctors or nurses present is independently related to awake ambulatory BP, controlling for office BP measured by mercury sphygmomanometer; the opposite is not true.
**IP04-018**

Ibesartan, through VEGF, regulates cardiac and glomerular angiogenesis of obese and type 2 diabetic db/db mice

Lei Liu, Keichihiro Kataoka, Taishi Nakamura, Masaya Fukuda, Hisato Nakao, Yi Fei Dong, Yoshiko Tokutomi, Hisao Ogawa, Shokei Mitsuyama

1Department of Pharmacology and Molecular Therapeutics, Kumamoto University School of Medicine, 2Department of Cardiovascular Medicine, Kumamoto University Graduate School of Medical Sciences

Objective: We investigated the molecular mechanism of protective effects of losartan, an AT1 receptor blocker, against renal and cardiac complications in obese and type 2 diabetic db/db mice. Methods and Results: db/db mice were orally given ibezartan (20 mg/kg/day) or vehicle for 4 weeks. Compared with vehicle group, ibezartan significantly ameliorated the excretion of urinary albumin, glomerular inflammation (macrophage infiltration) and sclerosis, and also significantly attenuated cardiac inflammation and fibrosis. These beneficial effects of ibezartan on cardiac complications in type 2 diabetes were associated with the amelioration of cardiological superoxide, and this attenuation of oxidative stress was attributed to the restoration of Cu/Zn SOD by ibezartan. In db/db mice, CD31(+) capillary density and vascular endothelial growth factor (VEGF) were increased in glomeruli, while decreased in the heart. Ibesartan significantly reduced CD31(+) capillary density in glomeruli in db/db mice and suppressed renal mRNA and protein expression of VEGF. On the other hand, ibezartan significantly increased cardiac CD31(+) capillary density, being associated with the enhanced cardiac mRNA and protein expression of VEGF. Conclusions: Our work demonstrates that ibezartan, probably through VEGF, enhances angiogenesis in the heart and inversely reduces angiogenesis in glomeruli of obese and type 2 diabetic mice, which may contribute to the protective effects of ibezartan against diabetic cardiological complications.

**IP04-019**

Effects of Methylene chloride and Ethyl acetate Fractions Isolated from Rubus coreanum on Catecholamine Secretion in the Adrenal Medulla

Dong-Yoon Lim

Department of Pharmacology (Cardiovasc. Lab), College of Medicine, Chosun University, Gwangju, Korea

The purpose of the present study was to examine the effects of [ethyl acetate (EtOAc) and methylene chloride (CH2Cl2)] fractions isolated from Rubus coreanum on release of catecholamines (CA) in the rat adrenal medulla and to compare those effects between them. EtOAc (20–180 microg/mL) or CH2Cl2 (20–180 microg/mL) fraction, perfused into an adrenal vein for 90 min, dose- and time-dependently inhibited the CA secretory responses evoked by ACh, high K+, DMPP and McN-A-343. Also, in the presence of EtOAc or CH2Cl2 fractions, the secretory responses of CA evoked by veratridine, Bay-K-8644, and cyclopiazonic acid were reduced, respectively. In the simultaneous presence of EtOAc or CH2Cl2 fraction plus L-NNAME, the CA secretion evoked by the above secretagogues were considerably recovered to the extent of the corresponding control compared with the inhibitory effect of EtOAc or CH2Cl2 fraction alone. In the presence of EtOAc or CH2Cl2 fraction, level of NO released from rat adrenal medulla was greatly increased. Collectively, these results demonstrate that EtOAc or CH2Cl2 fraction dose-dependently inhibits the CA secretory responses evoked by stimulation of cholinergic receptors as well as by direct membrane depolarization. It seems that EtOAc or CH2Cl2 fraction-induced inhibition is exerted by inhibiting both Na+- and Ca2+-channels on the adrenomedullary cell membrane as well as suppression of Ca2+ release from cytoplasmic calcium store at least through increased NO production due to activation of NO synthase. Based on these results, it is thought that EtOAc or CH2Cl2 fraction possesses the active components helpful to alleviate hypertension and angina pectoris.

**IP04-020**

Losartan Causes Dual Effects on Catecholamine Release in the Perfused Adrenal Medulla

Dong-Yoon Lim, Soon-Pyo Hong

1Department of Pharmacology (Cardiovasc. Lab), College of Medicine, Chosun University, Gwangju, Korea, 2Department of Internal Medicine (Cardiology), College of Medicine, Chosun University, Gwangju, Korea

The aim of this study therefore was to determine whether losartan could influence the CA release from the isolated perfused model of the rat adrenal medulla. Losartan (5–50 microM) perfused into an adrenal vein for 90 min produced dose- and time-dependently inhibited the CA secretory responses evoked by ACh (5, 32 mM), high K+ (56 mM), DMPP (100 microM) and McN-A-343 (100 microM). Losartan failed to affect basal CA output. Furthermore, in adrenal glands loaded with losartan (15 microM), the CA secretory responses evoked by Bay-K-8644 (10 microM), cyclopiazonic acid (10 microM), and veratridine (100 microM), were markedly inhibited. However, at a high concentration (150–300 microM), losartan as well as olmesartan (150–300 microM), losartan as well as olmesartan (150–300 microM) rather enhanced the CA secretion evoked by ACh. Collectively, these experimental results suggest that losartan at low concentrations inhibits the CA secretion evoked by cholargenic stimulation as well as by membrane depolarization from the rat adrenal medulla, but at high concentration it rather inhibits ACh-evoked CA secretion. It seems that losartan has dual action acting as both agonist and antagonist at nicotinic receptors of the isolated perfused rat adrenal medulla, which might be dependent on the concentration. It is also thought that this inhibitory effect of losartan may be mediated by blocking the influx of both Na+ and Ca2+ into the rat adrenomedullary chromaffin cells as well as by inhibiting the Ca2+ release from the cytoplasmic calcium store, which is thought to be relevant to AT1 receptor blockade, in addition to its enhancement effect on the CA release.

**IP04-021**

Correlations between different measures of clinic, home and ambulatory BP in hypertensive patients

Kazuo Eguchi, Naidj Kuruvilla, Joji Ishikawa, Gbenga Oggedgb, William Gerin, Joseph E. Schwartz, Thomas G. Pickering

1Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan, 2Center for Behavioral Cardiovascular Health, Columbia University Medical Center

Objectives: We performed this study to clarify the agreements among different measures of clinic, home and ambulatory BP. Methods: We enrolled 56 hypertensive patients (mean age; 65±14 years; 54% female). The study consisted of three clinic visits, self-monitoring of home BP between visits, and ambulatory BP (ABP) monitoring at the second visit. Patients were given a home BP monitor (HEM-5001, Omron, Japan) programmed to automatically take 3 consecutive readings at fixed intervals. They were asked to measure BP in the morning and evening for an 8-week period. The associations between clinic BP (mercury sphygmomanometer, HEM-5001, and HEM-907), home BP (the average of morning and evening, 2nd and 3rd BP readings), and average awake ABP were compared using the absolute values and intra-class correlation coefficients (ICC) for agreement. Results: The averages of office sphygmomanometer, office HEM-5001, office HEM-907, awake ABP, and home BP were 129/77 mmHg, 131/76 mmHg, 127/71 mmHg, 131/79 mmHg, and 133/77 mmHg, respectively. The office BP by two automated monitors was strongly correlated with that of mercury sphygmomanometer (ICC-agreements, both 0.95), especially HEM-5001 SBP/DBP readings. Home SBP was fairly correlated with awake ABP (ICC-agreement, 0.75), but mercury DBP was more closely correlated with awake DBP than was home DBP. Conclusions: Clinic BP measured with automated monitors could be used as an alternative for the evaluation of BP in the office. With somewhat less precision, home BP could be used as an alternative to awake ABP.
**IP04-022** Hypertension is a risk factor for depression in young-old female residents in Japan

Shigeto Morimoto1, Yoko Hamazaki1, Kumiko Wakabayashi1, Keiichiro Ishigami1, Li Zeng1, Atsumi Mikiko2, Yumi Koizumi1, Junta Sakai1, Hiroshi Yano1, Takeshi Nakahashi1, Koichi Nakamura1, Kazumi Fukuma1, Yoko Morikawa2, Tsumiya Kanda3, Hideaki Nakagawa2

1Department of Geriatric Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan
2School of Nursing, Kanazawa Medical University, Uchinada, Ishikawa, Japan
3Regional Comprehensive Support Center of Uchinada Town, Uchinada, Ishikawa, Japan
4Department of Epidemiology and Public Health, Kanazawa Medical University, Uchinada, Ishikawa, Japan
5Department of Community Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan

AIM: Depression is a common status in the elderly. However, the association of hypertension is not clarified, since both relatively lower and higher blood pressures were reported in subjects with dementia. The aim of present study is to elucidate association of hypertension to depression in the elderly.

SUBJECTS AND METHODS: Subjects studied were 840 young-old (65-74 years old, 361 males and 479 females), and 550 old-old (>75 years old, 197 males and 353 females) residents of Uchinada Town. Depression was evaluated by the short version of the Geriatric Depression Scale (≥2 in GDS-5). All the cross-sectional data of health examination in 2006 with possible association to depression by chi-square analysis or Mann-Whitney U test (p<0.20) were enrolled as confounding factors for multiple logistic regression analysis.

RESULTS: Morbidity rates of depression in males and females were 12% and 16% in the young-olds, and 21% and 31% in the old-olds, respectively. Present hypertension (>140/90 mmHg, including both untreated treated subjects) was a significantly (p=0.004) and independently associating factor for depression in the young-old female group, but not in other three groups.

CONCLUSION: Enough treatment of hypertension may be a key factor for prevention of depression in young-old females.

**IP04-023** SNPs in 9p21 locus associated with CAD confirmed by angiography in Japanese

Ada Congrains, Kei Kamide, Tomohiro Katsuya, Ryousuke Oguro, Izumi Shimaoka, Ken Sugimoto, Mitsuru Ohishi, Hiromi Rakugi

Department of Geriatric Medicine, Osaka University Graduate School of Medicine

Background: Genome wide association studies have consistently identified several SNPs on chromosome 9p21 as genetic risk factors of heart disease. Considering that the significant correlation between 9p21 loci and coronary artery diseases (CAD) does not point to any obvious physiological pathway yet, it is important to establish the association with precise clinical phenotypes.

Methods: We analyzed the association of two SNPs, rs1333049 and 2891168 with angiographically diagnosed coronary artery stenosis. We genotyped 668 individuals (231 subjects with angiographic CAD and 437 controls with no history of CAD).

Results: The association with CAD was significant for both SNPs, the strongest association was detected with rs1333049 after adjustment by age (P value=0.006) showing an odds ratio per C allele of 1.398 (95% CI from 1.114 to 1.753). Recent evidence suggests that the locus is mainly associated with early onset of CAD rather than progression of disease. To assess this association in our sample, we evaluated the relationship between the severity of diseases (number of stenotic lesion: 1, 2, 3) and these SNPs. There was no significant association with these SNPs in the present study.

Conclusion: Here, we confirmed the association in the locus 9p21, identifying rs1333049 as strongest associated SNP with CAD confirmed by angiography in Japanese. Further investigations aimed to clarify its mechanism are necessary.
KJS-1 Hypertension and Cerebral Small-Vessel Disease: A New Radiologic Marker?

Seung-Hoon Lee, MD, Ph.D.
Dept. of Neurology, Seoul National University Hospital, Seoul, Korea

Stroke is generally classified into ischemic and hemorrhagic stroke, and because of similarity of pathogenesis to coronary artery disease, large- vessel atherosclerosis appears to be considered as main cause of stroke. However, small-vessel disease arouses lacunar infarctions and intracerebral hemorrhage, which are attributed to over 40% of stroke incidence. Underlying vascular pathologic findings of small-vessel disease are lipohyalinosis, microatheroma, fibrinoid necrosis, microaneurysm, etc., which are mainly caused by chronic hypertension. These vascular lesions are responsible for ischemic (lacunar infarction and leukoaraiosis), or hemorrhagic damage (microbleeds and macrobleeds). The lesions were hardly identified in living human, but recent great advance of brain imaging including MRI enables us to identify the patients having small-vessel disease or the risk. Representatively, leukoaraiosis are easily seen on fluid-attenuated inversion recovery image (FLAIR) MRI as high intensity lesions in the periventricular area or the centrum semiovale. Microbleeds are visualized as minute signal loss lesions on T2*-weighted gradient-echo (GRE) MRI, which incorporates the dephasing of spins due to local magnetic field inhomogeneties. Leukoaraiosis are associated with incident ischemic stroke, depression, behavioral dysfunction and dementia. Recently, we firstly found that leukoaraiosis are associated with increased risk of mortality after intracerebral hemorrhage in a nation-wide cohort study. Microbleeds are closely associated with past , and future occurrence of symptomatic intracerebral hemorrhage. In addition, we found that microbleeds increase the risk of symptomatic intracerebral hemorrhage in warfarin-users. These radiological findings should be used as new radiological findings to indicate patients with high risk of small-vessel disease.

KJS-2 Hypertension and Stroke: Clinical Aspects in Japan

Kazunori Kario, MD, FACC, FACP, FAHA
Chairperson, Japan-Korea Joint Hypertension Organizing Committee, The Japanese Society of Hypertension
Professor and Chairman, Division of Cardiovascular Medicine Jichi Medical University School of Medicine

There is marked difference in the demographics of cardiovascular disease between Asian countries and Western countries. In Asian countries, stroke occurs more frequently than coronary artery disease. Blood pressure (BP) is linearly associated with stroke risk, and hypertension is the most powerful risk factor of stroke. Stroke risk is increased even in those with prehypertension (BP = 130-139/85-89 mmHg), which is determined by the modest increase in body mass index, and in normotensive subjects with left ventricular hypertrophy in a Japanese community-dwelling population. There is the growing evidence that out of clinic BP such as self-measured BP at home and ambulatory BP are more closely associated with stroke risk than clinic BP. In addition to the higher 24-hr BP level, the disrupted diurnal BP variation such as the riser pattern with higher nocturnal BP than awake BP is associated with cardiovascular risk, particularly in short sleepers. Exaggerated morning surge in BP is also associated with stroke risk in the hypertensive patients. The antihypertensive treatment targeting morning BP should be stressed to achieve the perfect 24-hr BP control including sleep and morning periods and more effective prevention for cardiovascular disease in the stroke-prone Asian countries.